Vaxcyte, Inc.
PCVX
$54.03
$0.040.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.07% | -15.82% | -27.77% | -18.37% | -2.65% |
| Total Depreciation and Amortization | -40.27% | 88.57% | 4.17% | 2.36% | 1.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.34% | -2.09% | 379.46% | -64.75% | -18.37% |
| Change in Net Operating Assets | 85.23% | -161.43% | -4.80% | 168.04% | -1,892.56% |
| Cash from Operations | -24.82% | -56.89% | -18.27% | 27.13% | -49.26% |
| Capital Expenditure | -75.68% | 30.09% | -23.49% | 63.53% | 10.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -276.95% | -7.26% | 52.25% | -41.70% | 128.47% |
| Cash from Investing | -302.74% | -4.99% | 55.86% | -36.96% | 122.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17,788.08% | 1,016.01% | -90.54% | -46.52% | 0.95% |
| Repurchase of Common Stock | -823.04% | 74.68% | -454.67% | 86.45% | -387.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24,882.68% | 165.60% | -245.79% | 231.75% | -84.53% |
| Foreign Exchange rate Adjustments | -477.27% | -39.52% | -63.63% | -31.74% | -13.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.11% | -319.84% | 36.38% | 2.24% | 93.81% |